RMTI (Rockwell Medical Inc.) stock: $7.73, $31.2M market cap, $24.8M cash, $13.6M EV, $38.4M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pending acquisition: Rockwell Medical is acquiring Vantive's in-center hemodialysis business. Figures on this page are Rockwell standalone, before the deal.
What they do
Unless otherwise indicated in this Annual Report on Form 10-K “we,” “our,” “us,” “the Company,” "Rockwell," “Rockwell Medical,” and other similar terms refer to Rockwell Medical, Inc., together with its consolidated subsidiaries. You are advised to read this Annual Report on Form 10-K in conjunction with other reports and documents that we file from time to time with the Securities and Exchange Commission (“SEC”).
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Common
4.0M
Pre-funded warrants
0.0M
Options
0.3M
RSUs
0.1M
Warrants
0.4M
Converts
0.0M
Conv preferred
0.1M
ESPP reserve
—
FDSO
5.0M
Cap table as of 2026-08-10.
Definitive agreement announced November 2, 2026 for Rockwell to acquire Vantive's in-center hemodialysis business in 35 jurisdictions for a base price of $125M, paid entirely with seller financing: $100M of term loans and a $25M convertible note from Vantive affiliates, plus up to $45M of earnout payments. No shares are issued at signing. At closing Rockwell will repay its existing Innovatus loan in full, take on the $100M of term loans, and issue the $25M convertible note, which converts at $14.94 per share (about 1.67M shares). Closing is expected in mid-2027, subject to regulatory approvals and Vantive's pre-closing separation of the business. The share counts, cash and debt on this page are Rockwell standalone and will be replaced at closing.
Stage not disclosed · ActiveModality: ferric pyrophosphate (iron replacement)
Aliases SFP (soluble ferric pyrophosphate)
Partnerships Charak, LLC: exclusive worldwide license to patents/information for Triferic (2002 agreement; Charak MSA Oct 2018 covering SFP for renal failure, IV SFP products, and TPN SFP products).
Indications
Treatment of patients with renal failure / iron disorders(Stage not disclosed)
Status note Commercial drug product within the hemodialysis concentrates business. Distribution/license agreements in China, India, South Korea, and Turkey terminated (deferred revenue fully recognized by Jun 2025). Filing excerpts do not state current approval/indication status.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.